A citation-based method for searching scientific literature

Jennifer J Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S Falchook, Apostolia M Tsimberidou, Sarina Piha-Paul, Roosevelt Anderson, Danxia Ke, Vincent Miller, Roman Yelensky, J Jack Lee, David S Hong, Razelle Kurzrock. Cancer Res 2016
Times Cited: 157







List of co-cited articles
510 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Maria Schwaederle, Barbara A Parker, Richard B Schwab, Gregory A Daniels, David E Piccioni, Santosh Kesari, Teresa L Helsten, Lyudmila A Bazhenova, Julio Romero, Paul T Fanta,[...]. Mol Cancer Ther 2016
110
36

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, Jennifer J Wheler, Gerald S Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra,[...]. Clin Cancer Res 2012
375
35

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
641
35

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari,[...]. Cancer Discov 2017
360
33

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Vladimir Lazar, Brian Leyland-Jones, Richard L Schilsky, John Mendelsohn, Razelle Kurzrock. JAMA Oncol 2016
189
25

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
257
24

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Daniel D Von Hoff, Joseph J Stephenson, Peter Rosen, David M Loesch, Mitesh J Borad, Stephen Anthony, Gayle Jameson, Susan Brown, Nina Cantafio, Donald A Richards,[...]. J Clin Oncol 2010
432
23

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Clin Oncol 2015
268
21

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
Garrett M Frampton, Alex Fichtenholtz, Geoff A Otto, Kai Wang, Sean R Downing, Jie He, Michael Schnall-Levin, Jared White, Eric M Sanford, Peter An,[...]. Nat Biotechnol 2013
21

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.
Apostolia-Maria Tsimberidou, David S Hong, Yang Ye, Carrie Cartwright, Jennifer J Wheler, Gerald S Falchook, Aung Naing, Siqing Fu, Sarina Piha-Paul, Filip Janku,[...]. JCO Precis Oncol 2017
91
23

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Tracy L Stockley, Amit M Oza, Hal K Berman, Natasha B Leighl, Jennifer J Knox, Frances A Shepherd, Eric X Chen, Monika K Krzyzanowska, Neesha Dhani, Anthony M Joshua,[...]. Genome Med 2016
148
21

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock. Mol Cancer Ther 2017
19

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
19

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
208
18

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
Denis L Jardim, Maria Schwaederle, Caimiao Wei, J Jack Lee, David S Hong, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Natl Cancer Inst 2015
122
16

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.
Apostolia-Maria Tsimberidou, Sijin Wen, David S Hong, Jennifer J Wheler, Gerald S Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape,[...]. Clin Cancer Res 2014
148
16

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
15

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
15

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
O Trédan, Q Wang, D Pissaloux, P Cassier, A de la Fouchardière, J Fayette, F Desseigne, I Ray-Coquard, C de la Fouchardière, D Frappaz,[...]. Ann Oncol 2019
80
17

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Funda Meric-Bernstam, Lauren Brusco, Kenna Shaw, Chacha Horombe, Scott Kopetz, Michael A Davies, Mark Routbort, Sarina A Piha-Paul, Filip Janku, Naoto Ueno,[...]. J Clin Oncol 2015
294
14

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
13

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
Fabrice André, Thomas Bachelot, Frederic Commo, Mario Campone, Monica Arnedos, Véronique Dieras, Magali Lacroix-Triki, Ludovic Lacroix, Pascale Cohen, David Gentien,[...]. Lancet Oncol 2014
273
13

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
Marilyn M Li, Michael Datto, Eric J Duncavage, Shashikant Kulkarni, Neal I Lindeman, Somak Roy, Apostolia M Tsimberidou, Cindy L Vnencak-Jones, Daynna J Wolff, Anas Younes,[...]. J Mol Diagn 2017
773
13

OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah M Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E Rudolph, Rona Yaeger, Tara Soumerai, Moriah H Nissan,[...]. JCO Precis Oncol 2017
960
13

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger, Andrew J Rowan, Stuart Horswell, M Math, James Larkin, David Endesfelder, Eva Gronroos, Pierre Martinez, Nicholas Matthews, Aengus Stewart,[...]. N Engl J Med 2012
12

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
11

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
11

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.
Richard B Lanman, Stefanie A Mortimer, Oliver A Zill, Dragan Sebisanovic, Rene Lopez, Sibel Blau, Eric A Collisson, Stephen G Divers, Dave S B Hoon, E Scott Kopetz,[...]. PLoS One 2015
425
10

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
10

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
10

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Pam K Mangat, Susan Halabi, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A Janeway, Philip J Stella, Emile Voest, Kathleen J Yost, Jane Perlmutter,[...]. JCO Precis Oncol 2018
66
15

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Kim M Hirshfield, Denis Tolkunov, Hua Zhong, Siraj M Ali, Mark N Stein, Susan Murphy, Hetal Vig, Alexei Vazquez, John Glod, Rebecca A Moss,[...]. Oncologist 2016
45
20

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
John D Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein,[...]. J Clin Oncol 2018
251
9

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
856
9


Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.
Maria Schwaederle, Hatim Husain, Paul T Fanta, David E Piccioni, Santosh Kesari, Richard B Schwab, Sandip P Patel, Olivier Harismendy, Megumi Ikeda, Barbara A Parker,[...]. Clin Cancer Res 2016
98
8

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Maria Schwaederle, Barbara A Parker, Richard B Schwab, Paul T Fanta, Sarah G Boles, Gregory A Daniels, Lyudmila A Bazhenova, Rupa Subramanian, Alice C Coutinho, Haydee Ojeda-Fournier,[...]. Oncologist 2014
119
8

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.
Shumei Kato, Nithya Krishnamurthy, Kimberly C Banks, Pradip De, Kirstin Williams, Casey Williams, Brian Leyland-Jones, Scott M Lippman, Richard B Lanman, Razelle Kurzrock. Cancer Res 2017
74
10

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, N Lopez-Bigas, C K Y Ng, P L Bedard, G Tortora, J-Y Douillard,[...]. Ann Oncol 2018
203
8

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Milan Radovich, Patrick J Kiel, Stacy M Nance, Erin E Niland, Megan E Parsley, Meagan E Ferguson, Guanglong Jiang, Natraj R Ammakkanavar, Lawrence H Einhorn, Liang Cheng,[...]. Oncotarget 2016
57
12

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
7

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
7

Institutional implementation of clinical tumor profiling on an unselected cancer population.
Lynette M Sholl, Khanh Do, Priyanka Shivdasani, Ethan Cerami, Adrian M Dubuc, Frank C Kuo, Elizabeth P Garcia, Yonghui Jia, Phani Davineni, Ryan P Abo,[...]. JCI Insight 2016
260
7


Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis J Kuo, Ramez N Eskander, Aaron Goodman, Natalie Galanina,[...]. Nat Commun 2020
84
8

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
619
7

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Himisha Beltran, Kenneth Eng, Juan Miguel Mosquera, Alexandros Sigaras, Alessandro Romanel, Hanna Rennert, Myriam Kossai, Chantal Pauli, Bishoy Faltas, Jacqueline Fontugne,[...]. JAMA Oncol 2015
203
6

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Filip Janku, David S Hong, Siqing Fu, Sarina A Piha-Paul, Aung Naing, Gerald S Falchook, Apostolia M Tsimberidou, Vanda M Stepanek, Stacy L Moulder, J Jack Lee,[...]. Cell Rep 2014
186
6

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Maria Schwaederle, Gregory A Daniels, David E Piccioni, Paul T Fanta, Richard B Schwab, Kelly A Shimabukuro, Barbara A Parker, Razelle Kurzrock. Mol Cancer Ther 2015
61
9

Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Martin E Gutierrez, Kelly Choi, Richard B Lanman, Edward J Licitra, Stanley M Skrzypczak, Ruth Pe Benito, Tommy Wu, Srikesh Arunajadai, Sukhi Kaur, Harry Harper,[...]. Clin Lung Cancer 2017
118
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.